NEW YORK – In metastatic castration-resistant prostate cancer (mCRPC), the progression-free survival benefit of adding AstraZeneca's investigational VEGF inhibitor cediranib to the PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza) may be limited to patients with homologous recombination repair (HRR)-deficient cancers, according to a new biomarker analysis presented Thursday during the American Society of Clinical Oncology's Genitourinary Cancers Symposium.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.